INTRODUCTION AND OBJECTIVES: Chemoresistance to cisplatin is a principal cause of treatment failure and disease progression of advanced bladder cancer. In the present study we explore the novel relationship between cisplatin resistance and pyruvate kinase 2 (PKM2) e a rate-limiting enzyme responsible for Warburg effect in cancer cells, and whether down-regulating PKM2 by RNAi or small molecules reduces chemoresistance and enhances chemosensitivity of bladder cancer cells to cisplatin.
METHODS: Cell lines from mouse and human bladder cancer and their derivatives expressing RNAi of PKM2 were assessed for their chemosensitivity to cisplatin or shikonin -a chemical inhibitor of PKM2, or both. The effects and mechanisms of PKM2 inhibition on cisplatinresistance were examined. Cisplatin and shikonin as single or dual agents for inhibiting bladder cancer proliferation and metastasis were further tested in syngeneic mice.
RESULTS: Shikonin binds PKM2 and inhibits bladder cancer cell proliferation in a dose-dependent but pyruvate kinase activity-independent manner. Down-regulation of PKM2 by shRNA blunts cellular responses to shikonin but enhances the responses to cisplatin. Shikonin and cisplatin together exhibit significantly greater growth inhibition and apoptosis than when used alone. Experimentally induced cisplatinresistance is strongly associated with PKM2 overexpression, and cisplatin-resistant cells respond sensitively to shikonin. In syngeneic mice, shikonin and cisplatin together, but not as single-agents, markedly reduces bladder cancer growth and lung metastases.
CONCLUSIONS: PKM2 overexpression is a key mechanism of natural and acquired chemoresistance of bladder cancer to cisplatin. Inhibition of PKM2 via RNAi or chemical inhibitors may be a highly effective approach to overcome chemoresistance and improve the outcome of advanced bladder cancer.
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MP98-17 TARGETING PROTEIN KINASE D2 MAY REPRESENT A THERAPEUTIC STRATEGY FOR BLADDER CANCER
Mohammad siddiqui*, Iawen Hsu, Quentin Li, Thomas Sanford, Reema Railkar, Piyush Agarwal, Bethesda, MD INTRODUCTION AND OBJECTIVES: Protein Kinase D (PKD) is downstream of protein kinase C and it can regulate cell survival, proliferation, invasion, and migration. It has been implicated in several cancers and exists in three major isoforms. We sought to investigate the role of PKD2 in bladder cancer.
METHODS: PKD2 protein expression was assessed using Oncomine data for normal urothelium and bladder tumors. Several bladder cancer cell lines (T24, T24T, UMUC1, and TCCSUP) were assessed for cell proliferation, growth in low attachment agar (GILA), invasion, and migration with and without stable knock-down of PKD2. The UMUC1 cell line was evaluated in xenografts for tumor growth with and without stable knock-down of PKD2. A flank xenograft experiment was performed with oral gavage in mice using CRT0066101, a pan-PKD inhibitor. Western blot analysis was used to confirm silencing and evaluate downstream targets of PKD2.
RESULTS: Oncomine data confirmed increased mRNA expression of PKD2 in bladder tumors compared with normal urothelium. Selective knock-down of PKD2 in the cell lines inhibited cell proliferation, GILA colony formation, invasion, and migration. UMUC1 cells with silenced PKD2 failed to grow tumors in xenografts. Tumor xenografts treated with CRT0066101 had significant tumor growth inhibition compared to tumor controls (p<0.0001). Loss of phosphorylated c-Jun, a key mediator of cell proliferation and apoptosis, is noted with PKD2 silencing and PKD pharmacologic inhibition.
CONCLUSIONS: PKD2 is overexpressed in bladder tumors and inhibition of PKD2 either through selective silencing of PKD2 or the use of a pan-PKD inhibitor results in tumor growth inhibition in cell lines and xenografts. Targeting PKD2 results in loss of active c-Jun and may represent a therapeutic strategy in urothelial cancer. METHODS: To evaluate differential gene expression according to different platinum sensitivity in human bladder cancer cells, we conducted microarray analysis-based gene expression profiling with cisplatin sensitive (T24) and resistant (T24R2) human bladder cancer cells and the results were validated by Western blot analysis. To test synergism between drugs combination index based on CCK-8 assay and also colony forming assay were used. To determine mechanisms underlying synergistic interaction between drugs, flow cytometry and Western blot analysis were performed.
Source of
RESULTS: Gene expression profiling showed that the expression of 5,021 and 1,727 genes had more than two-fold and four-fold changes between T24 and T24R2 cells after platinum treatment. Especially Hsp90 (HSP90AA1, HSP90AA2) and RAS-MEK-MAPK and PI3K-AKT-mTOR signaling pathways showed significantly different expressions in the two cell lines. The combination of NVP-BEZ235 and satraplatin showed strong synergistic antitumor effect in cisplatinresistant T24R2 cells. However, we found that both NVP-BEZ235 monotherapy and combination treatment with satraplatin caused increased phosphorylation of MEK1/2 and ERK1/2 despite of the suppression of PI3K/AKT signaling in T24R2 cells. The addition of 17-DMAG, HSP90 inhibitor to NVP-BEZ235 and satraplatin combination therapy down regulated both AKT and ERK signaling and synergistically enhanced antitumor effect in T24R2 cells through the caspasedependent apoptosis and phase-specific cell cycle arrest.
CONCLUSIONS: The present study demonstrated that HSP90 plays important role for the platinum resistance in human bladder 
INTRODUCTION AND OBJECTIVES:
The molecular mechanisms of muscle invasion and distant metastasis in bladder cancer (BC) are not well understood. MicroRNA (miRNA) expression signature of various human cancers have reported that miR-26a-5p/-26b-5p were frequently downregulated in cancer tissues, suggesting these miRNAs act as tumor-suppressors. However, their functions in BC remains unknown. The aim of this study was to investigate the functional role of /-26b-5p and to identify molecular targets that contribute to metastasis in BC.
METHODS: Expression of miR-26a-5p/-26b-5p and their target genes were evaluated in 69 BC clinical BC specimens and 23 normal bladder epithelia (NBE) by real-time PCR. We performed gain-of-function studies (cell proliferation, migration and invasion) by using miR-26a/b transfectants in BC cell lines (T24 and BOY). Putative target genes were listed by in-silico study using the gene expression omnibus (GEO) and TargetScan. We performed loss-of-function studies by using si-RNA transfectants to evaluate the functional role of the target gene. Luciferase reporter analyses were employed to validate direct binding between the target gene and miR-26a/b in BC cells. Overall survival (OS) of the BC patients was evaluated by the Kaplan-Meier analysis.
RESULTS: The expression levels of miR-26a-5p/-26b-5p in clinical BCs were significantly downregulated compared to that in NBE (p < 0.0001 and p ¼ 0.0006, respectively). miR-26a-5p/-26b-5p transfectants significantly suppressed cell migration and invasion, suggesting these miRNAs act as tumor-suppressors. Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) was identified as a direct regulation of miR-26a-5p/-26b-5p by luciferase reporter assay. Kaplan-Meier analysis revealed that the patients with higher PLOD2 expression showed lower overall survival probabilities than those with lower expression (p ¼ 0.0153). Loss-of-function study showed that cell migration and invasion were significantly inhibited in si-PLOD2 transfectans.
CONCLUSIONS: PLOD2 was directly regulated by tumor-suppressive miR-26a-5p/-26b-5p, and might be good prognostic markers for survival of BC patients. Recent studies showed that PLOD2 function as a collagen cross-linking enzyme associate with extracellular matrix (ECM) stiffness. Aberrant expression of PLOD2 by regulation of these miRNAs might cause extracellular matrix (ECM) disruption and promoting metastasis. Tomoya Fukawa*, Terumichi Shintani, Kei Daizumoto, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan INTRODUCTION AND OBJECTIVES: Toll-like receptors (TLRs) play important roles in immune response and have been reported that expression levels of these molecules were related to prognoses of several kinds of cancer. It has been reported that the expression level of TLR4 is reduced in bladder cancer. However, the role of TLR4 in bladder cancer is still unclear. The aim of this study is to clarify the effects of TLR4 expression on prognosis of bladder cancer patients and to elucidate its underlying mechanisms.
Source of
METHODS: To evaluate the effects of TLR4 expression on prognosis, we analyzed the clinical outcomes of 95 patients with bladder cancer and also conducted immunohistochemistry for TLR4 in bladder cancer specimens. The cancer-specific survival was determined by Kaplan-Meier method and the statistical significance was examined by Log-rank test. We also performed multivariate analysis to evaluate the relationship between TLR4 expression and clinical outcomes. We checked the effects of TLR4 depletion on cell growth and invasive abilities of bladder cancer cells. To clarify the underlying mechanisms, we also analyzed the gene expression profiles in TLR4depleted cells. These results were validated by quantitative RT-PCR. We also confirmed our finding by using data from public database.
RESULTS: The expression levels of TLR4 were inversely correlated with local invasion and worse prognosis (log-rank test, p¼0.007). Although the effect of TLR4 depletion on cell growth was small, it could dramatically enhance invasion ability of cancer cells. We also observed morphologic changes in these cells. Both gene ontology analysis and gene set enrichment analysis of microarray data revealed that most of upregulated genes in TLR4-depleated cells were related to differentiation of epithelium cells. Among these genes, small proline-rich protein (SPRR) family genes which are related to poor prognosis of squamous cell carcinoma were upregulated in TLR4-depleated cells. By analyzing data from public database, we confirmed that expression levels of SPRRs family genes were inversely correlated with TLR4 expression and positively correlated with poor prognosis of bladder cancer patients. Furthermore, we found that expression of TLR4 diminished in the areas with squamous differentiation in bladder cancer.
CONCLUSIONS: Our finding suggested that TLR4 is related to bladder cancer aggressiveness through regulation of squamous differentiation.
